Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

Research

Home/Research
27 01, 2016

Isn’t battling myeloma hard enough without having to raise money, too?

Tags: , , |4 Comments

An amazing over-the-top (pun intended) multiple myeloma awareness and fundraising mountain climbing adventure scaling Mr. Kilimanjaro sponsored by the MMRF: https://m.facebook.com/media/set/?set=a.10153334017497918&type=3&l=f16f8c5178 February 1st, CrowdCare Foundation will launch a safer, but just as exciting Muscles for Myeloma Challenge fundraiser. Our Pat's Myeloma Beach Walk will be part of the extended project. More about that soon. Both

21 01, 2016

MMRF 2015 myeloma year in review

Tags: , , |1 Comment

I'm part of a Cure Talk Radio broadcast in a few hours featuring Multiple Myeloma Research Foundation co-founder, Anne Quinn Young. If you can't listen live, I'll pass along a link so you an listen later. Here's a short rundown about the show: 2015 saw a lot of action in the Myeloma world. Four new

16 01, 2016

Blood Glucose, MGUS, Myeloma & Metformin (Part Nine)

1 Comment

A lot has happened since I ran two of the final installments about the importance of controlling blood glucose by Danny Parker: Blood Glucose, MGUS, Myeloma & Metformin (Part Seven and Eight)   ASH, unscheduled trips to the ICU, Iowa City drama. A lot went wrong in December. I'm still having trouble bouncing back from

2 01, 2016

The power of combination therapies

Tags: , , , |4 Comments

New checkpoint inhibitor studies combining the experimental drug, Keytruda, with Revlimid, are working in patients who have become refractory to Revlimid. I found this great article on Linkedin.com on Saturday. I didn't even know there was such a thing. I thought that Linkedin was a professional job networking site. Apparently, professionals in healthcare can post

29 12, 2015

Key research breakthroughs at ASH

Tags: , |0 Comments

Did you see the MMRF's outline of important myeloma related news at ASH this year? Short and to the point. American Society of Hematology (ASH) Key Takeaways Earlier this month the MMRF attended the 57th Annual Meeting of the American Society of Hematology (ASH) in Orlando, Florida. In last month’s newsletter, Blake Morrison, PharmD MMRF

22 12, 2015

Hopeful news about first PD-1 inhibitor

Tags: , , , |2 Comments

Another exciting, new immunotherapy may be on the horizon: Keytruda In meetings of well informed patient activists and experts after ASH, several in the group were excited about a new class of drug called PD-1 inhibitors. Jenny Ahlstrom was practically doing back flips over it. Here's info on the first of let's hope are several

14 12, 2015

Back to ASH: Ninlaro and Pomalyst combo promising

Tags: , , , |0 Comments

Before I pass along important information about Takeda's new oral proteasome inhibitor, Ninlaro (ixazomib), I wanted to share an update about how I'm doing. Much better, thank you very much!  Squirting a shot of vancomycin liquid into the back of my mouth (yuck) every six hours seems to be doing the trick. Another antibiotic, Flagyl,

8 12, 2015

More drugs are good, but aren’t enough

Tags: , , , , , |9 Comments

Data for more than a dozen "new" myeloma drugs was presented at this week's American Society of Hematology (ASH) meetings here in Orlando. As I described yesterday, several are hopeful crossover drugs; compounds that are already FDA approved for use against other cancers. Keytruda, known chemically as pembrolizumab, and ricolinostat (ACY-1215), another possible cross over

7 12, 2015

BREAKING NEWS: Early data featuring Darzalex in combination with Revlimid

Tags: , , , |6 Comments

As promised, here are details from a preliminary study showing impressive response rates when Darzalex (daratumumab) is combined with Revlimid and dexamethasone. Similarly impressive numbers were also achieved when the immunotherapy drug was used along with pomalidomide. I'll pass along those details later today after that data is presented. Back to Darzalex and Revlimid. Very

4 12, 2015

Has bad timing left ASH irrelevant?

Tags: , , |2 Comments

I'm almost packed. Tomorrow I'll be driving three hours south to Orlando to attend my 7th American Society of Hematology (ASH) annual meeting. Seven years! How the multiple myeloma therapy landscape has changed. Heck, things have been turned upside down in three short weeks. The Washington Post ran an impressive article about it on Wednesday:

1 12, 2015

More about elotuzumab (Empliciti). Are immunotherapies the answer?

Tags: , , , , , |0 Comments

In my haste to get the news out about elotuzumab's FDA approval yesterday, I mistakenly relied on a Cure Magazine article that stated Kyprolis was the drug used in combination with elo. I was surprised, but ran with it. I should have known better. The Cure Magazine article was mistaken. Elotuzumab (Empliciti), Revlimid and dexamethasone